Lymphoma & Myeloma 2015 took place October 22-24 in New York, New York.

Breast cancer drug may also work in MCL, myeloma

Print Friendly, PDF & Email


mm_bma.jpg
Bone marrow aspirate
showing multiple myeloma

Targeting the cell cycle with cyclin-dependent kinase (CDK) inhibitors may be an effective strategy to treat lymphoma and myeloma, according to a presentation at Lymphoma & Myeloma 2015. Palbociclib, an inhibitor of CDK4 and CDK6, received accelerated approval from the US Food and Drug Administration to treat advanced breast... [Read Article]

Print Friendly, PDF & Email

Post-ibrutinib management in MCL unclear, speaker says

Print Friendly, PDF & Email


mantle_cell_lymphoma.jpg
Mantle cell lymphoma

Despite an “unprecedented” single-agent response rate and progression-free survival (PFS) in previously treated mantle cell lymphoma (MCL) patients, those with multiple risk factors have a dismal outcome following ibrutinib failure. So after ibrutinib, what’s next in MCL? That was the question asked at Lymphoma & Myeloma 2015. Peter Martin, MD, of Weill... [Read Article]

Print Friendly, PDF & Email

Reprogramming the immune system

Print Friendly, PDF & Email


hodgkin_lymphoma_copyright_2010_nephron_wiki_230.jpg
Electron micrograph
showing Hodgkin lymphoma

Using a 3-pronged approach to reprogram the immune system—inhibition of critical pathways, activation of others, and depletion of malignant cells—may be the best strategy to optimize immune function in B-cell lymphomas, according to Stephen M. Ansell, MD, PhD, of the Mayo Clinic in Rochester, Minnesota.“[A]ll told, there are multiple... [Read Article]

Print Friendly, PDF & Email

Median DOR, PFS not yet reached for ibrutinib in CLL

Print Friendly, PDF & Email


imbruvica-janssen_220.jpg
Ibrutinib (Imbruvica) capsules
Photo courtesy of
Janssen Biotech, Inc.

Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms that the Bruton’s tyrosine kinase inhibitor produces rapid and durable responses in patients with chronic lymphocytic leukemia (CLL), according to an update presented at Lymphoma & Myeloma 2015. At up to 44... [Read Article]

Print Friendly, PDF & Email

The search continues for additional targets in CLL

Print Friendly, PDF & Email


CLL_peripheral_blood_smear_showing_Credit_Mary_Ann_Thompson_210.jpg
Peripheral blood smear
showing CLL
Image by Mary Ann Thompson

Despite enormous advances in therapies for chronic lymphocytic leukemia (CLL) that target the B-cell receptor (BCR) signaling pathway, there is still room for improvement, according to investigators at the Mayo Clinic. Bruton’s tyrosine kinase (BTK) and phosphoinositide-3 kinase delta (PI3Kδ) inhibitors are major... [Read Article]

Print Friendly, PDF & Email

Ibrutinib may prove useful in MM, research shows

Print Friendly, PDF & Email


multiple_myeloma_bone_marrow_aspirate_showing_230.jpg
Bone marrow aspirate
showing multiple myeloma

Results of an open-label, phase 2, dose-escalation study of ibrutinib combined with low-dose dexamethasone suggest the Bruton’s tyrosine kinase (BTK) inhibitor may be useful in treating relapsed or relapsed and refractory patients with multiple myeloma (MM). In the highest dose cohort, 23% of patients experienced a clinical benefit,... [Read Article]

Print Friendly, PDF & Email